COVID-19 future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Line 94: | Line 94: | ||
| | | | ||
| | | | ||
* Sensitivity to mutagenesis | |||
* Excellent B and T cell response | |||
| | | | ||
|} | |} |
Revision as of 13:35, 17 March 2020
COVID-19 Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
COVID-19 future or investigational therapies On the Web |
American Roentgen Ray Society Images of COVID-19 future or investigational therapies |
Risk calculators and risk factors for COVID-19 future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Future or Investigational Therapies
Immune Targets
- The B cell and T cell epitopes derived from the spike (S) and nucleocapsid (N) proteins are currently under investigation as immune targets for development of vaccine.
- Phylogenetic similarity between SARS-CoV and COVID-19 at the level of structural proteins S, E, M, and N is providing guidance for development of a possible vaccine.
Prior Work
The following table depicts major vaccine products that have been developed against SARS-CoV and MERS-CoV:
Vaccine Base | Antigen | Clinical Testing | Pros | Cons |
---|---|---|---|---|
DNA |
|
Phase I, II
(NCT03721718) |
|
|
Viral Vector |
|
Phase I
(NCT03399578, NCT03615911) |
|
|
Conjugated subunit |
|
|
||
Virion |
|
|
||
Inactivated |
|
|
||
Live attenuated |
|
|